Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM)

Trial Profile

Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM)

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Maraviroc (Primary) ; Raltegravir (Primary) ; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms OPTIPRIM
  • Most Recent Events

    • 22 Jan 2018 Results of estimation of residual drug concentrations (Ctrough) and exposures (AUC) by using published pharmacokinetic models published in the Journal of Antimicrobial Chemotherapy
    • 26 Jul 2017 Results of pharmacokinetic substudy presented at the 9th International AIDS Society Conference on HIV Science
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top